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Aims Risk estimation is important to motivate patients to adhere to treatment and to identify those in whom additional
treatments may be warranted and expensive treatments might be most cost effective. Our aim was to develop a
simple risk model based on readily available risk factors for patients with stable coronary artery disease (CAD).
...................................................................................................................................................................................................
Methods
and results
Models were developed in the CLARIFY registry of patients with stable CAD, first incorporating only simple clinical
variables and then with the inclusion of assessments of left ventricular function, estimated glomerular filtration rate,
and haemoglobin levels. The outcome of cardiovascular death over 5 years was analysed using a Cox proportion-
al hazards model. Calibration of the models was assessed in an external study, the CORONOR registry of patients
with stable coronary disease. We provide formulae for calculation of the risk score and simple integer points-
based versions of the scores with associated look-up risk tables. Only the models based on simple clinical variables
provided both good c-statistics (0.74 in CLARIFY and 0.80 or over in CORONOR), with no lack of calibration in
the external dataset.
...................................................................................................................................................................................................
Conclusion Our preferred model based on 10 readily available variables [age, diabetes, smoking, heart failure (HF) symptom
status and histories of atrial fibrillation or flutter, myocardial infarction, peripheral arterial disease, stroke, percutan-
eous coronary intervention, and hospitalization for HF] had good discriminatory power and fitted well in an exter-
nal dataset.
...................................................................................................................................................................................................
Study
registration
The CLARIFY registry is registered in the ISRCTN registry of clinical trials (ISRCTN43070564).
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Introduction
Stable coronary artery disease (CAD) is a major cause of death and
disability and a growing component of the global cardiovascular (CV)
burden. According to the American Heart Association report 2017,
CAD remains responsible for one-third or more of all deaths in indi-
viduals over age 35 years.1 Stable CAD encompasses a spectrum of
syndromes with heterogeneous risks, including patients who may or
may not have experienced a previous acute coronary syndrome or
undergone revascularization.2 Given this diversity, stratification of
risk has been recommended by European and American guidelines
to help guide the management of patients.2,3 Estimates of risk can be
used in discussions with patients to help motivate the need for risk
reducing interventions and encourage adherence to evidence-based
therapies including lifestyle modification and secondary prevention
drugs. The increasing cost of care is a major challenge for all health-
care systems. Health economic analysis plays an important role par-
ticularly for novel therapies. Treatments that provide the same
relative benefit, independent of absolute risk, will be most cost effect-
ive when used to treat the highest risk patients. Risk models can be
used for cost-effectiveness stratification.
The objective of this article is to develop a risk model for adverse
outcomes in patients with stable CAD. To have widest applicability,
the ideal risk model should be relatively simple and based on risk fac-
tors routinely recorded in clinical practice. Risk models derived from
older cohorts have been criticized.4 Since CV event rates have been
falling, a successful risk model must reflect contemporary risk. Risk
models have been developed for patients with stable CAD, some
derived for specific subpopulations such as patients with anginal
symptoms,5–7 patients with suspected angina attending a chest pain
clinic,8 survivors of acute coronary syndromes,9 populations including
less stable participants with recent myocardial infarction (MI),10 and
patients recruited to clinical trials.9–11 Many of these models do not
reflect current clinical practice or absolute CV risk. A model has
been developed for a UK primary care context using routinely col-
lected data from a large UK general practice population12 as has a
model incorporating N-terminal pro–B-type natriuretic peptide (NT-
proBNP) and high-sensitivity cardiac troponin T (hs-cTnT).13
A model has been reported based on a cohort of patients from a spe-
cific geographic area in northern France.14,15 Likewise, a simple point-
based model was based on the REduction of Atherothrombosis for
Continued Health (REACH) registry.16,17 However, REACH
included 27% of participants without a history of CAD and started
enrolment in 2003.
We have created models for patients with stable CAD based on
readily available risk factors collected in the prospeCtive observa-
tional LongitudinAl RegIstry oF patients with stable coronary arterY
disease (CLARIFY),18 with validation in an external dataset, the ‘Suivi
d’une cohorte de patients COROnariens stables en re´gion NORd-
pas-de-Calais’ (CORONOR) observational study.15
Methods
The CLARIFY registry
The CLARIFY registry has been described in detail elsewhere.19 Briefly,
CLARIFY was an observational registry of over 33 000 patients with
stable CAD, enrolled in 45 countries between 2009 and 2010 with a tar-
get follow-up of 5 years. Consecutive patients were enrolled by 2898
investigators, with each investigator enrolling 10–15 consecutive patients
over a short time period. The first patient was included on 26 November
2009 and recruitment was completed on 30 June 2010. Inclusion required
any of the following four criteria (not mutually exclusive): previous MI (at
least 3 months prior to enrolment), evidence of coronary stenosis >50%,
proven symptomatic MI, or prior revascularization procedure. The main
exclusion criteria were serious non-CV disease and conditions interfering
with life expectancy or severe other CV disease [including advanced
heart failure (HF)]. Follow-up visits were annually for five 5 years, al-
though some final visits were conducted late, interspersed with 6-month
telephone calls. Baseline characteristics of the population included in our
risk models and numbers of CV deaths observed in subgroups are given
in Supplementary material online, Table S1.
Risk model derivation
Our aim was to provide a contemporary risk model based on risk factors
that have been identified previously. We expected left ventricular ejec-
tion fraction (LVEF) and available laboratory variables in the CLARIFY
dataset to potentially be important predictors. However, current esti-
mates of these quantities were not always available in patients’ notes, par-
ticularly in participants recruited in primary care. Hence, we decided to
develop models, both including and excluding LVEF and laboratory
markers. We restricted our populations to participants who had com-
plete assessments of the parameters relevant to each model. Most partic-
ipants in CLARIFY had complete data when LVEF and laboratory markers
were excluded. Laboratory markers investigated were estimated glom-
erular filtration rate (eGFR), haemoglobin, total cholesterol, and low and
high density lipoprotein cholesterol levels. There was a significant degree
of non-availability of recent measurements of LVEF and laboratory
markers. In addition, varying combinations of total, low, and high density
lipoprotein cholesterol levels were recorded, further reducing availability
of these measurements. In the reduced datasets, these cholesterol meas-
urements had limited independent prognostic value and hence were not
considered further. The participants provided written informed consent
for participation in the study. All of the study data were collected, man-
aged, and analysed at the Robertson Centre for Biostatistics, University
of Glasgow.
The clinical outcome evaluated in this study was CV death. This out-
come included deaths of unknown cause in the derivation and validation
cohorts. We were concerned that there would be heterogeneity in the
use of coronary revascularization across the countries included in
CLARIFY and, as the outcomes in CLARIFY were not adjudicated, stroke
and hospitalization for HF would represent less reliable events. Initial
analyses including MI in the endpoint resulted in models with reduced dis-
criminatory power. Cardiovascular death is a key outcome for patients
with stable CAD. It is defined more reliably in a study without endpoint
adjudication and is more relevant than all-cause mortality in terms of pos-
sible modification in a population with CAD.
Statistical methods
To make our model more useful in clinical practice, we were advised to
minimize the number of variables included in the model, with an objective
of including no more than 10 variables. To this end we fitted stepwise
Cox proportional hazards regression models using P-values of 0.05 to
enter or remove variables. If the model contained more than 10 variables
we focused on the first 10 variables selected. Stepwise fitting of models
has been criticized, particularly with relatively small datasets relative to
the number of variables investigated. However, it has been noted18 that
selected predictor variables with very small P-values (say, <0.001) are
2 I. Ford et al.
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..much less prone to selection bias and overfitting than weak predictors
with P-values near the nominal significance level. With the exception of
age, continuous variables were categorized mainly on clinical grounds or
based on percentiles of their distributions. After the fitting of models, cat-
egories were merged where there was little evidence of variation in risk.
Continuous variables were summarized by mean and standard deviation
and categorical variables by counts and percentages. Hazard ratios, 95%
confidence intervals (CIs), and associated P-values were reported from
fitted Cox models for binary and continuous explanatory variables, and
overall P-values were reported for categorical variables with more than
two categories, along with hazard ratios, 95% CIs, and P-values for con-
trasts of individual categories relative to a referent category. Curves
describing the cumulative risk of CV death were calculated as cumulative
incidence functions, correcting for the competing risk of non-CV death.
The ability of the models to discriminate between those with or with-
out an outcome was assessed using Harrell’s c-statistic.20 A risk score
was calculated for each participant based on each fitted model. The popu-
lation was divided into 10 categories split by the deciles of the risk score.
Observed numbers of events were calculated and expected numbers of
events were derived from the sums of the martingale residuals from the
fitted model in each category and summarized graphically. Calibration of
the models was assessed by testing the significance of the 10-category
variable when it was added to the model.21 Validity of the proportional
hazards assumption was assessed visually from the cumulative incidence
functions split into fifths of the distribution of the risk score and by testing
the interaction of the risk score with the logarithm of time in the Cox
model.
The risk scores and estimated risks can be calculated using the coding
instructions in Supplementary material online, Appendix S2 and coeffi-
cients and formulas provided in Supplementary material online, Tables
S4–S6. We also developed a simplified integer points-based scoring sys-
tem with associated look-up table for estimating risk. Instructions for cal-
culating the integer points-based score are given in Supplementary
material online, Appendix S3, with the integer points-based allocation
system and a look-up table for estimating risk provided in Supplementary
material online, Tables S7–S10.
External validation
The discriminatory power of the models was validated externally in an in-
dependent dataset, consisting of 4094 patients from the CORONOR ob-
servational registry that prospectively enrolled consecutive patients with
stable CAD, median follow-up 5 years. As previously published,14,15
patients were included by 50 cardiologists from the region Nord-Pas-de-
Calais in France if they had evidence of stable coronary disease defined by
MI or coronary revascularization (at least 1 year previously), or obstruc-
tion of at least 50% of the luminal diameter of at least one native vessel
on coronary angiography. Unlike CLARIFY, there were no exclusions
based on other CV or non-CV illnesses or comorbidities. Calculation of
Harrell’s c-statistic was as for the internal assessment in CLARIFY. The
biggest challenge for any prognostic model, even one with good discrim-
inatory power, is to achieve good calibration in external datasets.
Calibration was assessed using a measure of calibration-in-the-large for a
model in an external dataset.22 In addition, we assessed the performance
of the REACH risk model15 for CV death within 20 months of follow-up
in the CLARIFY study.
Results
Risk score derivation
In the main paper we focus on the results for top 10 predictor mod-
els. Results for the additional models containing all variables included
in the stepwise regression fits are given in the Supplementary material
online, Appendix. The CLARIFY population used for deriving the risk
scores excluding LVEF and laboratory variables comprised 32 361
patients [1619 CV deaths, median (lower quartile–upper quartile) fol-
low–up 5 (4.4–5.1) years, total follow-up 143 747 person-years] for
the top 10 predictor model. When LVEF and laboratory variables
were allowed to enter the model, the corresponding numbers were
15 768 patients [839 CV deaths, median (lower quartile–upper quar-
tile) follow-up 5 (4.8–5.1) years, total follow-up 71 421 person-years]
for the top 10 predictors model. Summary statistics, hazard ratios,
....................................................................................................................................................................................................................
Table 1 Preferred model: multivariable risk model incorporating the top 10 predictors of cardiovascular death, omit-
ting left ventricular ejection fraction and laboratory variables (N5 32 361)
Predictor Statistic HR (95% CI) PHR Pgroup v
2
Age (per 5 years) 64.2 (10.5) 1.36 (1.33–1.40) <0.0001 490
Diabetes On insulin 2029 (6.3) 2.17 (1.86–2.53) <0.0001 <0.0001 107
Referent: not diabetic Not on insulin 7356 (22.7) 1.38 (1.23–1.54) 0.0001
Smoking status Current 4037 (12.5) 1.78 (1.51–2.09) <0.0001 <0.0001 55
Referent: never Former 14 967 (46.3) 1.34 (1.20–1.49) <0.0001
AF/flutter 2284 (7.1) 1.75 (1.53–2.00) <0.0001 67
MI 19 396 (59.9) 1.51 (1.36–1.68) <0.0001 57
PAD 3199 (9.9) 1.39 (1.22–1.58) <0.0001 25
PCI 18 952 (58.6) 0.72 (0.66–0.80) <0.0001 41
Stroke 1300 (4.0) 1.54 (1.29–1.83) <0.0001 24
Admission for CHF 1510 (4.7) 2.24 (1.93–2.60) <0.0001 113
CHF symptoms 4899 (15.1) 1.44 (1.27–1.62) <0.0001 <0.0001 35
Hazard ratios and P-values for the variables included in the model. Statistics are n (%) with the exception of age which is summarized as mean (SD). All binary HRs have referent
of not having the characteristic specified. For categorical variables with more than two categories, overall P-values for the variables are also given. Conditional v2 statistics are
given for each variable.
AF, atrial fibrillation; CI, confidence interval; CHF, congestive heart failure; HR, hazard ratio; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous cor-
onary intervention; SD, standard deviation.
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..95% CIs, and P-values are given for the variables included in each
model in Table 1 (Model 1: top 10 predictors excluding LVEF and la-
boratory variables) and Table 2 (Model 2: top 10 predictors including
LVEF and laboratory variables). Age, histories of diabetes, atrial fibril-
lation or flutter, MI, peripheral arterial disease, and hospitalization for
HF were included in all models. For Model 1, histories of smoking,
percutaneous coronary intervention (PCI), stroke, and current HF
were also included. For Model 2, current symptoms of angina, ele-
vated systolic blood pressure (over 160 mmHg), lower eGFR [esti-
mated using the Chronic Kidney Disease Epidemiology Collaboration
(CKD EPI) formula], and impaired LVEF were included. For Model 3,
elevated systolic blood pressure, low diastolic blood pressure
(<70 mmHg), low body mass index, and high pulse rate (>_80 b.p.m.)
were included, in addition to the variables in Model 1. For the full
model including LVEF and laboratory variables, histories of smoking
and PCI, low haemoglobin, low body mass index, and high pulse rate
(>_80 b.p.m.) were included in addition to the variables in Model 2.
When included in models, baseline factors associated with increased
risk of CV death were being older, being current or former smokers
or diabetic, having current anginal symptoms, having histories of atrial
fibrillation/flutter, MI, peripheral arterial disease, stroke, or hospital-
ization for HF, not having a history of PCI, having current HF symp-
toms, higher systolic blood pressure, and lower diastolic blood
pressure, having a raised pulse, reduced eGFR, lower LVEF, and
lower body mass index.
When the study population was split into fifths of the distributions
of the fitted risk scores, the estimated cumulative incidence functions
for the outcome of CV death (shown in Figure 1) for Models 1 and 2
demonstrated an approximately linear cumulative incidence of the
primary endpoint in each fifth of risk, as would be expected in a stable
population. For each model, there was a stepwise increase in the
incidence by fifth, with the top fifth being at particularly high risk. The
variables included in Model 1 are summarized, split by fifths of the dis-
tribution of estimated risk in Supplementary material online, Table
S11. The distributions of the risk scores and estimated 5-year risks
for this model are provided in Supplementary material online, Figures
S3 and S4. As well as being older, participants in the top fifth of risk
have particularly high rates of insulin-dependent diabetes, atrial fibril-
lation or flutter, previous history of stroke, or hospitalization for HF
and current symptoms of HF. The c-statistics for the top 10 predic-
tors models were 0.74, 95% CI (0.72–0.75) for Model 1 and 0.75,
95% CI (0.74–0.77) for Model 2. The observed and expected counts
in the 10 categories of the risk scores are shown in Figure 2 for
Models 1 and 2. The plots visually suggest good calibration with bor-
derline evidence of lack of calibration in the statistical tests for Model
1. More detailed analysis suggests that any lack of calibration is only
evident for patients with very low risk. There is no evidence of lack of
calibration for Model 2. The almost linear separation of the cumula-
tive incidence curves for each model supports the proportional haz-
ards assumptions as do the P-values when testing the interaction
between the risk score and the logarithm of time, with all P-values
>_0.22. As a sensitivity analysis we also investigated the discriminatory
power of the models in subgroups based on male/female and
Caucasian/non-Caucasian splits. The c-statistics were very similar in
the subgroups for all models.
External validation
In the CORONOR validation set, for Model 1, 318 of 4075 patients
died from CV causes [c-statistic 0.80, 95% CI (0.77–0.82)]. The corre-
sponding result for Model 2 was 291 events in 3622 patients [c-statis-
tic 0.81, 95% CI (0.78–0.83)]. The P-values for the assessment of
calibration-in-the-large were 0.136 and <0.001 for Models 1 and 2,
....................................................................................................................................................................................................................
Table 2 Multivariable risk model incorporating the top 10 predictors of cardiovascular death, including left ventricu-
lar ejection fraction and laboratory variables (N515 768)
Statistic HR (95% CI) PHR Pgroup v
2
Age (per 5 years) 63.3 (10.5) 1.28 (1.23–1.33) <0.0001 161
Diabetes On insulin 1152 (7.3) 1.87 (1.52–2.30) <0.0001 <0.0001 40
Referent: not diabetic Not on insulin 3774 (23.9) 1.34 (1.15–1.56) 0.0003
Current angina 4160 (26.4) 1.23 (1.06–1.42) 0.0067 7
AF/flutter 1194 (7.6) 1.73 (1.44–2.07) <0.0001 34
MI 10 028 (63.6) 1.42 (1.21–1.66) <0.0001 19
PAD 1624 (10.3) 1.50 (1.26–1.79) <0.0001 21
Admission for CHF 950 (6.0) 1.97 (1.64–2.38) <0.0001 51
eGFR (mL/min/1.73 m2) <30 225 (1.4) 2.64 (2.94–3.58) <0.0001 <0.0001 49
Referent: >_60 30–44.99 839 (5.3) 1.62 (1.30–2.01) <0.0001
45–59.99 2383 (15.1) 1.29 (1.09–1.55) 0.0035
LVEF (%) <40 1232 (7.8) 2.79 (2.30–3.38) <0.0001 <0.0001 113
Referent: >50 40–50 3728 (23.6) 1.64 (1.40–1.93) <0.0001
SBP >_160 mmHg 1154 (7.3) 1.61 (1.30–1.99) <0.0001 20
Hazard ratios and P-values for the variables included in the model. Statistics are n (%) with the exception of age which is summarized as mean (SD). All binary HRs have referent
of not having the characteristic specified. For categorical variables with more than two categories, overall P-values for the variables are also given. Conditional v2 statistics are
given for each variable.
AF, atrial fibrillation; CI, confidence interval; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular ejection fraction;
MI, myocardial infarction; SBP, systolic blood pressure; PAD, peripheral arterial disease; SD, standard deviation.
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Figure 1 (A) Cumulative incidence of cardiovascular death as first event for Model 1, by fifths of the risk score distribution in the CLARIFY popula-
tion. (B) Cumulative incidence of cardiovascular death as first event for Model 2, by fifths of the risk score distribution in the CLARIFY population.
Figure 2 (A) Calibration chart for Model 1 in the CLARIFY study dataset, comparing observed and expected numbers of events split by tenths of
the distribution of the estimated risk with P-value for lack of fit. The mean estimated 5-year risks in the tenths are 1.03%, 1.71%, 2.28%, 2.86%, 3.51%,
4.31%, 5.32%, 6.76%, 9.26%, and 19.42%. (B) Calibration chart for Model 2 in the CLARIFY study dataset, comparing observed and expected numbers
of events split by tenths of the distribution of the estimated risk with P-value for lack of fit. The mean estimated 5-year risks in the tenths are 1.07%,
1.65%, 2.15%, 2.65%, 3.24%, 3.99%, 5.01%, 6.55%, 9.53%, and 22.96%.
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..respectively, with the lack of fit for Model 2 suggesting that the model
significantly underestimated the risk of patients in the CORONOR
study.
The REACH risk score for CV death within 20 months was calcu-
lated within CLARIFY. This score yielded a creditable c-statistic of
0.72. However, the estimated 20 months event rate of 1.99% overes-
timated the observed CLARIFY risk by28% indicating a lack of cali-
bration, P-value <0.001.
Discussion
Summary and discussion of the findings
We have created simple risk models within a large international regis-
try of patients with stable CAD. We have validated the discrimin-
atory power of the models in an unselected registry of patients from
the north of France (CORONOR). We describe in detail two risk
models, based on restriction to the top 10 predictors of outcome,
with and without the exclusion of measures of LVEF and laboratory
parameters. Further models based on all predictors included in the
stepwise regression models are described in the Supplementary ma-
terial online, Appendix. All models performed well in terms of dis-
crimination. Despite this, the models excluding LVEF and laboratory
parameters were the only models that showed no evidence of lack of
calibration-in-the-large in external validation, an important property
of any prognostic model. Although the formal test for lack of calibra-
tion in CLARIFY for Model 1 is borderline significant, we note that
this result is likely due to the high power in a very large study to de-
tect small discrepancies which were evident only for patients at very
low risk. Hence, our strong recommendation is that the Model 1
should be used because of its simplicity, good discrimination and cali-
bration. Although Model 2 has a good c-statistic in CLARIFY and, in
CORONOR, the lack of evidence that this model is well calibrated in
an external dataset suggests that it should not be used. The explan-
ation for the lack of calibration of Model 2 in CORONOR is unclear.
However, this could be due to the fact that Model 2 could only be fit-
ted in <50% of the participants in CLARIFY, a subset that might not
be representative of the typical patients with stable CAD. The add-
itional models in the Supplementary material online, Appendix,
including all predictors in the stepwise models, do not provide any
major improvement over the simpler models including only the top
10 predictors.
The directions of the hazard ratios for factors in the risk model are
consistent with previous studies, with history of PCI and low systolic
blood pressure (in a model containing raised systolic blood pressure
as a risk factor) being the only medical history variables associated
with lower risk. There has been variation in the hazard ratio associ-
ated with previous coronary revascularization in other studies. This
likely depends on the underlying population studied and other factors
included in the model and on whether coronary artery bypass graft is
included or is the variable studied. In patients with previous MI,10
including those with events in the 3 months prior to inclusion, previ-
ous revascularization was associated with increased risk, while in
more general populations with stable CAD6,9,15 like CLARIFY, previ-
ous revascularization was associated with lower risk. A likely explan-
ation is the well-documented selection bias, whereby patients
selected for revascularization, particularly PCI, tend to be younger
and lower risk, whereas older more severe patients, with more
advanced comorbidities can be recused by heart teams and managed
conservatively.
Strengths of the approach
Given the improvement in outcomes in patients with acute coronary
syndromes,23 CV mortality has decreased relative to non-CV causes
of death.24 It was therefore important to exclude non-CV causes of
death from the primary outcome and focus on CV death. The
strengths of the models include their simplicity, the facts that they are
more contemporary than previous models and that they were
derived from a large heterogeneous international registry of consecu-
tively recruited patients, with successful validation of two of the mod-
els in an external cohort study. CLARIFY and CORONOR had high
rates of use of evidence-based secondary prevention therapies14,15,19
and were not restricted to the highly selected patient populations
from randomized clinical trials.25,26
Limitations of the research
There are limitations to the present analysis: events in CLARIFY
were not adjudicated but investigator reported, and there may be
some uncertainty about the reliability of the diagnosis of CV death in
studies of outpatients. However, all data were monitored in 5% of
the sites, which were randomly selected throughout the study with
no major discrepancies detected. We expect that information
regarding causes of death from volunteer investigators would be at
least as good as and probably much better than information collected
from death certificates. The discriminatory powers of our models are
good, with particularly strong external validation of three of the mod-
els in the CORONOR study. However, there is always room for im-
provement. It seems likely that improvements in the discriminatory
power would require either inclusion of a greater number of varia-
bles, including socioeconomic (e.g. social deprivation, attained educa-
tional level or other surrogates) or psychological variables (e.g.
anxiety, depression) which may be difficult to measure or define,12 or
the inclusion of more sophisticated imaging or biomarker data that
may not currently be routinely available in patients’ records. In the
near future, automated availability of a greater number of variables
via electronic health records will likely allow easy access to more
refined risk stratification, as already demonstrated.12 However, at
present, the information required for the CLARIFY risk score is read-
ily available to most physicians caring for patients with stable CAD. It
is also true that c-statistics are driven not just by the model, but also
by the heterogeneity of risk in the population studied. This is likely
the explanation of the improved c-statistics in CORONOR, a study
based on a less selected group of patients than CLARIFY. CLARIFY
represents a more homogeneous group of patients with stable CAD,
excluding those who are frail or at very high risk of future events. c-
Statistics can be manipulated by including unstable patients who are
patently at high risk without the need for evaluation with a risk
model. The LVEF measurement used in CLARIFY was not standar-
dized and could be collected by echocardiography, nuclear imaging,
magnetic resonance imaging or angiography. Standardized measure-
ments would likely have reduced variability and may have improved
some of the models. However, this is often impossible to achieve in
6 I. Ford et al.
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large multinational observational longitudinal studies of unselected
patients. As noted above, stepwise regression has been criticized as
method of model building. However, we note that all of the variables
included in our preferred model are highly statistically significant
(P< 0.0001), suggesting there is likely to be little bias in our
approach.19
Other approaches
To put our preferred model into context, as noted in the introduc-
tion, previous models have been based on specific subpopulations
such as patients with angina,5–7 have been based on older clinical tri-
als9,11 or disease registries16 or have focused of a complex set of vari-
ables collected in primary care12 or have been based on populations
including unstable patients10 or patients without CAD.16 More re-
cently two models focusing on patients with stable CAD have been
developed that incorporate specific biomarkers such as NT-proBNP
or hs-cTnT. A four variable model, including these variables, for the
outcome of CV death, non-fatal MI, or stroke was developed that
achieved modest c-statistics of 0.73 and 0.65 in the derivation and val-
idation cohorts, respectively, with evidence of overestimation of risk
in the top three tenths of the distribution of risk in the validation co-
hort.27 A second model for the outcome of CV death, incorporating
seven variables, achieved c-statistics of 0.81 and 0.78. However, in
the derivation cohort there was evidence of an increasing magnitude
of overestimation of risk for annual risks >1%.13 A weakness of this
study in predicting outcomes with stable CAD is that the derivation
study included patients as early as 1 month post-MI. Although these
models show promise, they also illustrate the challenges of validating
models in external populations. On this basis, we feel that the
CLARIFY risk model makes an important contribution to risk predic-
tion in patients with stable CAD.
We assessed the performance of the REACH risk score in
CLARIFY. This model had reasonable discriminatory power but
overestimated the risk in the CLARIFY population indicating a lack of
calibration to a more contemporary population. While other models
are available, there is no established model that is widely or preferen-
tially used at present. In addition, several of the models require varia-
bles that were not available in the CLARIFY registry. In the future,
availability of rich datasets may allow head-to-head comparisons of
models and selection of the most parsimonious and effective ones.
Nevertheless, our simple models, not requiring a measurement of
LVEF or laboratory parameters, and yet achieving c-statistics >0.8 in
external validation, set a high threshold to improve upon.
Concluding remarks
Any risk model cannot of course be the sole basis of decision-making
for the treatment of individual patients. Rather, risk estimation should
be used to form an overall clinical decision, together with an assess-
ment of the individual levels of available risk factors included and not
included in the model along with comorbidities and the potential for
adverse effects of any treatment being considered. We do not rec-
ommend the use of our preferred risk model in patients with un-
stable CAD or in high risk patients with HF.
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